Canaccord Genuity reiterates a 'Buy' on PhotoMedex (PHMD); 'Beat and Raise'
Tweet
Share
E-mailGet Alerts PHMD Hot Sheet
Price: $1.07 --0%
Rating Summary:
2 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
2 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on PhotoMedex (NASDAQ: PHMD) price target of $22.00.
Analyst, William J. Plovanic, said, "We reiterate our rating after the release of strong Q1/12 results that demonstrate the continued growth potential of the company’s consumer business. Additionally, initial results of pilot DTC marketing programs for the physician recurring revenue business are encouraging and position the company for significant growth in this segment. Our thesis remains intact as the company executes on all fronts."
For an analyst ratings summary and ratings history on PhotoMedex click here. For more ratings news on PhotoMedex click here.
Shares of PhotoMedex closed at $18.34 yesterday.
Analyst, William J. Plovanic, said, "We reiterate our rating after the release of strong Q1/12 results that demonstrate the continued growth potential of the company’s consumer business. Additionally, initial results of pilot DTC marketing programs for the physician recurring revenue business are encouraging and position the company for significant growth in this segment. Our thesis remains intact as the company executes on all fronts."
For an analyst ratings summary and ratings history on PhotoMedex click here. For more ratings news on PhotoMedex click here.
Shares of PhotoMedex closed at $18.34 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mizuho Reiterates Outperform Rating on Broadcom Limited (AVGO) Into EPS
- Beike (BEKE) PT Raised to $23 at Morgan Stanley
- DA Davidson Starts Comfort Systems USA (FIX) at Buy
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS ViewSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
